Tag: Diabetes: Type II
ACC: Semaglutide Beneficial in Patients With T2DM and Peripheral Artery Disease
Semaglutide associated with increased walking distance in patients with symptomatic peripheral artery disease and type 2 diabetes
Minimal TV Viewing May Cut ASCVD Risk in Those With T2DM Genetic Risk
Medium and high T2DM genetic risk not linked to increased risk for ASCVD when TV viewing is no more than one hour/day
Risk for Specific Hematologic Cancers Down With GLP-1 Receptor Agonist Use in T2DM
GLP-1 RA use linked to lower risks for myelodysplastic syndromes, myeloproliferative neoplasms compared with metformin
Sotagliflozin Cuts MACE Rate in Patients With T2DM, CKD, CVD Risk Factors
Sotagliflozin can also significantly reduce the rate of myocardial infarction and stroke compared with placebo
Nonarteritic Anterior Ischemic Optic Neuropathy Increased With Semaglutide
Increase in NAION associated with semaglutide use among individuals with type 2 diabetes
Probability of Cardiovascular Events Lower in Type 1 Diabetes Versus Type 2
Type 1 diabetes associated with less myocardial infarction, percutaneous coronary intervention, stroke, and limb ischemia
Depression Risk Lower With GLP-1 Receptor Agonists Versus DPP-4 Inhibitors in Seniors
Modestly lower risk for depression seen compared with DPP-4i use, but not compared with SGLT-2i use
Certain Glucose-Lowering Meds Associated With Lower Risk for COPD Exacerbations
Lower risk for COPD exacerbations seen with SGLT-2 inhibitors and GLP-1 receptor agonists, but not with DPP-4 inhibitors
Age Differences Seen in Efficacy of Type 2 Diabetes Treatments
SGLT2 inhibitors more cardioprotective in older versus younger people despite smaller reduction in HbA1c with older age
Micronutrient Deficiencies Seen in More Than 45 Percent With Type 2 Diabetes
Pooled prevalence higher for women than men; vitamin D was most prevalent micronutrient deficiency
